相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)
Thomas Cluzeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao et al.
FRONTIERS IN ONCOLOGY (2020)
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
Lionel Ades et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
David Andrew Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tim-3 finds its place in the cancer immunotherapy landscape
Nandini Acharya et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
Brian J. Ball et al.
BLOOD ADVANCES (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Andrew M. Brunner et al.
BLOOD (2020)
TIM3 comes of age as an inhibitory receptor
Yochai Wolf et al.
NATURE REVIEWS IMMUNOLOGY (2020)
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
Michael R. Savona et al.
LANCET HAEMATOLOGY (2019)
Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia
Dongdong Feng et al.
BLOOD (2018)
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Amer M. Zeidan et al.
BLOOD (2018)
Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Wolfram C. M. Dempke et al.
EUROPEAN JOURNAL OF CANCER (2017)
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
S. Jilg et al.
LEUKEMIA (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Ronan T. Swords et al.
BLOOD (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
Function and regulation of Cullin-RING ubiquitin ligases
MD Petroski et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells
M Ohh et al.
EMBO REPORTS (2002)
A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination
VN Podust et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Nedd8 modification of Cul-1 activates SCFβTrCp-dependent ubiquitination of IκBα
MA Read et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
